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Supplementary Material 
	  
Inclusion	  criteria	  for	  intracranial	  artery	  dissection	  patients	  in	  published	  series	  are	  listed	  in	  Supplementary	  Panel	  1.	  While	  some	  studies	  included	  all	  types	  of	  
intracranial	  artery	  dissection,1-­‐5,19-­‐24	  several	  studies	  have	  focused	  exclusively	  on	  vertebrobasilar	  intracranial	  artery	  dissection6-­‐15,27-­‐35	  	  intracranial	  artery	  
dissection	  with	  subarachnoid	  haemorrhage15,16,25,2632,37-­‐45	  or	  intracranial	  artery	  dissection	  without	  subarachnoid	  haemorrhage.7,17,18,46,47	  Some	  studies	  
restricted	  the	  analysis	  to	  patients	  treated	  with	  a	  certain	  interventional	  approach.7,9,13,16,22,24,28,30-­‐34,37,40,42,43	  	  
All	  studies	  were	  retrospective	  and	  based	  on	  less	  than	  400	  patients,	  and	  37	  of	  50	  studies	  (74·∙0%),	  comprising	  2,592	  out	  of	  2,973	  patients	  (87·∙2%)	  were	  
conducted	  in	  Asia.	  In	  the	  main	  manuscript	  we	  are	  referring	  primarily	  to	  larger	  studies	  including	  40	  or	  more	  intracranial	  artery	  dissection	  patients,	  the	  smaller	  












 Supplementary Panel 1: Clinical criteria of included studies 
Author, journal, year Country Inclusion period Criteria 
Studies including more than 40 patients       
Yamaura, Neuropathology 20001 Japan 1995-1996 SAH, brain ischaemia or headache 
Mizutani, J Neurosurg 20112 Japan 1985-2008 IAD 
Ono, Stroke 20133 Japan 1980-2000 IAD 
Kwak, Neurointerv 20114* Korea 2000-2007 CeAD and IAD 
Metso, Stroke 20075 Finland 1994-2004 CeAD with intracranial involvement and IAD 
Ahn, Radiology 20126† Korea 2001-2010 symptomatic intracranial vertebrobasilar artery dissection 
Kim, Stroke 20117† Korea 2001-2008 symptomatic vertebrobasilar artery IAD  and aneurysm with endovascular treatment 
Matsukawa, Cerebrovasc Dis 20128‡ Japan 2003-2012 vertebral artery IAD 
Kashiwasaki, Neuroradiology 20139 Japan 1998-2011 vertebral artery IAD without PICA involvement treated with endovascular internal trapping 
Takemoto, Acta Neurochir 201010 Japan 1995-2007 symptomatic vertebral artery IAD 
Shin, Eur Neurol 201411§ South Korea, USA 2002-2010 symptomatic extra- and intracranial vertebral artery dissections 
Nakazawa, Neurorad J 201112 Japan 2004-2010 vertebral artery IAD 
Jin, AJNR 200913* Korea 1997-2007 vertebrobasilar artery IAD and aneurysm with endovascular treatment 
Zhao, Eur Radiol 2014 14| | China 2000-2011 Vertebral artery IAD and endovascular treatment 
Nakajima, Acta Neurochir 201015 Japan 2003-2006 SAH symptomatic vertebral artery IAD 
Zhao, Plos One 201316 | | China 200-2011 SAH vertebral artery IAD treated with stent(s)-assisted coiling 
Kim, Neurology 20117† Korea 2001-2008 symptomatic unruptured vertebrobasilar artery IAD 
Kai, Neurosurgery 201117 Japan 2003-2009 non-SAH symptomatic vertebral artery IAD 
Matsukawa, JNNP 201418‡ Japan 2003-2013 unruptured vertebral artery IAD with conservative treatment  
Studies including 20-40 patients       
Lasjaunias, Childs Nerv Syst 200519 France not specified intracranial aneurysm in children under 15 years 
Mohammadian, Neurol Res Int 201320 Iran 2008-2012 symptomatic IAD 
Li, J Clin Neurosc 201121# Australia 2003-2008 symptomatic IAD 
So, Clin Neurol Neurosurg 201422# Australia 2003-2011 IAD with endovascular treatment 
Pelkonen, Acta Radiol 200423 Finland 1982-2002 CeAD and IAD 
Wakhloo, Stroke 200824 USA 1996-2007 IAD and aneurysm with endovascular treatment 
Anxionnat, Neurosurgery 200325 France 1985-2000 SAH IAD  
Wong, Surg Neurol Int 201026 Hong Kong 2005-2010 SAH IAD 
Rabinov, AJNR 200327 USA 1992-2002 vertebrobasilar artery IAD 
Hosoya, Stroke 199928 Japan 1996-1997 vertebral artery IAD without PICA involvement treated with endovascular internal trapping 
Lee, Yonsei Med 200729 Korea 1992-2005 symptomatic vertebral artery IAD 
Park, AJNR 200930†,§ Korea 2001-2007 symptomatic vertebrobasilar artery IAD and aneurysm with stent-only therapy 
Taha, Turk Neurosurg 201031 Japan 1997-2006 vertebral artery IAD with endovascular treatment 
Albuquerque, Neurosurg Focus 200532 USA 1997-2005 symptomatic vertebral artery IAD with aneurysm and endovascular treatment 
Lv, AJNR 201033 China 2001-2007 symptomatic vertebral artery-PICA IAD with endovascular treatment 
Yoon, Acta Neurochir 201034 Korea 2003-2008 vertebrobasilar artery  IAD with stent-alone treatment 
Kim, AJNR 200835§ Korea 2001-2007 symptomatic basilar artery IAD 
Nam, JNIS 201436 Korea 2005-2014 vertebrobasilar artery IAD with endovascular treatment 
Endo, J Neurosurg 201337 Japan 2006-2011 SAH vertebral artery IAD with endovascular treatment 
Ramgren, Neurorad 200538 Sweden 1993-2003 SAH vertebrobasilar artery IAD 
Yuki, J Neurosurg 200539 USA 1994-2003 SAH vertebrobasilar artery IAD 
Shibukawa, Hiroshima J Med Sci 200940 Japan 1998-2008 SAH vertebral artery IAD with endovascular treatment 
Lee, Acta Neurochir 201041 Korea 2001-2009 symptomatic ruptured and unruptured aneurysms in vertebral artery IAD 
Sugiu, Neurorad 200542 Japan 1992-2002 SAH vertebral artery IAD with surgical or endovascular treatment 
Kurata, AJNR 200143 Japan 1996-1999 SAH vertebral artery IAD with endovascular treatment 
Yamada, J Neurosurg 200444 Japan 1990-2000 SAH vertebral artery IAD with conservative treatment 
Zhao, Acta Neurochir 200745 France 1989-2006 SAH vertebrobasilar IAD 
Arauz, Eur J Neurol 201346 Mexico 1990-2011 symptomatic intra- and extracranial vertebral artery dissection with acute infarction, who did not undergo surgical or endovascular treatment 
Naito, Neurosurg 200247 Japan 1988-2001 vertebral artery IAD initially without SAH 
Han, Eur Radiol 201448 Korea 2012-2013 clinical symptoms and CTA suspicious of vertebrobasilar IAD 
Oran, Diagn Interv Radiol 200949 Turkey 2002-2008 SAH posterior circulation, non- vertebral artery IAD 
SAH=subarachnoid haemorrhage. IAD=intracranial artery dissection. CeAD=cervical arterial dissection. PICA=posterior inferior cerebellar artery. 
*, †, ‡, §, | |, # these series partly overlap 
Supplementary Table 1: Clinical and radiological characteristics of IAD patients in published series including 20 to 40 patients 
Paper N Origin Imaging performed Age, yrs (range) Men Location Presenting symptoms 
All types               
Lasjaunias19 33 France not specified 5·7 57·6% 48·5% anterior; 51·1% posterior circulation SAH (13, 39·4%) 
Childs Nerv Syst   Radiology   (8 days- 15 years)  SAH: 46·2%  SAH: 38·5%/61·5%; non-SAH 55·0%/ 45·0% headache alone (11, 33·3%) 
2005        SAH: 4·7   non-SAH: 65·0% ICA (10), ACoA (1), MCA (5), BA (6), VA (6),   non-haemorrhagic deficit (8, 24·2%) 
         non-SAH: 6·3   PICA (3), SCA (1), PCA (1) asymptomatic (1, 3·0%) 
Mohammadian20 30 Iran DSA in all 50 (25-77) 53·3% 43·3% anterior; 56·7% posterior circulation SAH (25, 83·3%) 
Neurol Res Int   Neurology    SAH: 51   SAH: 52·0%  SAH: 44·0%/56·0%; non-SAH 40·0%/60·0% cerebral infarction (2, 6·7%) 
2013   Neurosurgery    non-SAH: 47   non-SAH: 60·0% ICA (5), MCA (5), ACA (3), VA (12), PCA (5)   
Li21* 25 Australia MRA, CTA, DSA  SAH: 50 40·0% 44·0% anterior; 56·0% posterior circulation SAH (13, 52·0%) 
J Clin Neurosc   Neurology    non-SAH: 39  SAH: 38·5%  SAH: 23·1%/76·9%; non-SAH 66·7%/33·3% cerebral ischaemia (12, 48·0%) 
2011   Neurosurgery      non-SAH: 41·7% ICA (11), VA (12), BA (2)   
    Radiology           
So22* 23 Australia DSA in all 47 (13-70) 43·5% 4·3% anterior; 95·7% posterior circulation SAH (16, 69·6%) 
Clin Neurol    Neurology    SAH: 43  SAH: 31·3%  SAH: 6·3%/93·8%; non-SAH 0%/100% headache (3, 13·0%) 
Neurosurg   Radiology    non-SAH: 54  non-SAH: 71·4% ICA (1), VA (12), BA (3), PICA (4), AICA (1),   cerebral ischaemia (2, 8·7%) 
2014           PCA (2) asymptomatic (2, 8·7%) 
Pelkonen23 22 Finland DSA, MRA 43 (1-62)§ 67·9%§ 54·5% anterior; 45·5% posterior circulation SAH (5, 22·7%) 
Acta Radiol   Radiology        SAH: 0%/100%; non-SAH 70·6%/29·4%  SAH and ischaemia (1, 4·5%) 
2004           ICA (9), MCA (3), VA (7), BA (1), PICA (1), PCA (1) 
            1 (4·8%) IAD in the VA was bilateral    
Wakhloo24 20 USA DSA in all, MRI in some 51 (29-72) 30·0% 70·0% anterior; 30·0% posterior circulation SAH (3, 15·0%) 
Stroke   Neurosurgery    SAH: 34  SAH: 66·7%  SAH: 33·3%/66·7%; non-SAH 76·5%/23·5% headache (5, 25·0%) 
2008   Radiology    non-SAH: 54  non-SAH: 23·5%  ICA (9), MCA (4), VA (3), BA (4) [presence of stroke not clearly  
              specified] 
SAH IAD               
Anxionnat25 27 France DSA in all 48 (16-74) 48·1% 3·7% anterior; 96·3% posterior circulation SAH (27, 100%) 
Neurosurgery   Neurology        ACA (1), VA (19), BA (2), PICA (2), SCA (2), PCA (2) 
2003   Neurosurgery       1 (3·7%) IAD in the VA was bilateral   
Wong26 23 Hong Kong not specified 56 43·5% 34·8% anterior;  65·2% posterior circulation SAH (23, 100%) 
Surg Neurol Int   Radiology       ICA (4), ACA (3), MCA (1), VA (15), PCA (1)   
2010               
        
Vertebrobasilar IAD              
Rabinov27 34| | USA not specified 51 (17-87) 64·7% only vertebrobasilar IAD included SAH (29, 85·3%) 
AJNR   Neurosurgery    SAH: 52  SAH: 65·5%    SAH and stroke (5, 17·2%) 
2003   Radiology    non-SAH: 46  non-SAH: 60·0%    headache (2, 5·9%) 
              stroke (3, 8·8%) 
Hosoya28 31 Japan DSA and MRI in all 55 (25-82) 64·5% only vertebral IAD included SAH (3, 9·7%) 
Stroke   Neurosurgery       14 (45·2%) IADs were bilateral  headache alone (1, 3·2%) 
1999   Radiology         cerebral ischaemia (15, 48·4%) 
Lee29 28 Korea CT and MRI in all, MRA  52 (34-74) 50·0% only vertebral IAD included SAH (23, 82·1%) 
Yonsei Med J   Neurosurgery in some  SAH: 51  SAH: 39·1%   cerebral ischaemia (5, 17·9%) 
2007   Radiology    non-SAH: 52  non-SAH: 100%     
Park30†,‡ 27 Korea CT/CTA, MRI/MRA, DSA 46 (24-71) 63·0% only vertebrobasilar IAD included SAH (11, 40·7%) 
AJNR   Neurosurgery    SAH: 48  SAH: 54·5%    headache alone (10, 37·0%) 
2009   Radiology    non-SAH: 44  non-SAH: 68·8%   cerebral ischaemia (5, 18·5%) 
              mass effect (1, 3·7%) 
Taha31 25 Japan DSA, MRA, CTA 50 (38-66) 77·8% only vertebral IAD included SAH (17, 68·0%) 
Turk Neurosurg   Neurosurgery    SAH: 52  SAH: 76·5%   headache (1, 4·0%) 
2010   Radiology    non-SAH: 48  non-SAH: 100%   cerebral ischaemia (1, 4·0%) 
Albuquerque32 23 USA DSA in all 49 (35-72) 43·5% only vertebrobasilar IAD included SAH (17, 73·9%) 
Neurosurg Focus   Neurosurgery         cerebral ischaemia (2, 8·7%) 
2003             headache (3, 13·0%) 
Lv33 22 China DSA in all, CT and MR  43 (12-59) 68·2% only vertebral IAD included SAH (16, 72·7%) 
AJNR   Neurosurgery in some  SAH: 44  SAH: 62·5%   headache (2, 9·1%) 
2010        non-SAH: 41  non-SAH: 83·3%   cerebral ischaemia (4, 18·2%) 
Yoon34 22 Korea DSA, CTA, MRI in all 50 (24-65) 50% only vertebrobasilar IAD included SAH (6, 27·3%) 
Acta Neurochir   Neurosurgery       2 (9·1%) IADs  were bilateral cerebral ischaemia (2, 9·1%) 
2010           VA (23), BA (1) headache (5, 22·7%) 
              asymptomatic (3, 13·6%) 
Kim35† 21 Korea CT/CTA, MRI/MRA, DSA 53 (24-78) 57·1% only basilar IAD included SAH (10, 47·6%) 
AJNR   Neurosurgery         cerebral ischaemia (10, 47·6%) 







DSA and CTA in all 
haemorrhagic patients, MRI 
in non-haemorrhagic 
patients 
54 (34-70) 50·0% only vertebrobasilar IAD included 
 
SAH (14, 53·8%) 
SAH vertebrobasilar IAD            
Endo37 38 Japan DSA in all 53 (30-82) 50·0% only vertebral IAD included SAH (38, 100%) 
J Neurosurg   Neurosurgery           
2013   Radiology           
Ramgren38 29 Sweden DSA in all 55 (41-73) 34·5% only vertebrobasilar IAD included SAH (29, 100%) 
Neurorad   Radiology       VA (23), BA (4), PICA (2)   
2005               
Yuki39 29 USA DSA in all 45 44·8% only vertebrobasilar IAD included SAH (29, 100%) 
J Neurosurg   Radiology       VA (27), BA (2)   
2005               
Shibukawa40 26 Japan DSA in all 52 (36-74) 61·5% only vertebral IAD included SAH (26, 100%) 
Hiroshima J Med Sci Neurosurgery           
2009               
Lee41 25 Korea DSA in all 45 (22-66) 56·0% only vertebral IAD included SAH (25, 100%) 
Acta Neurochir   Neurosurgery           
2010   Radiology           
Sugiu42 25 Japan not reported 55 (37-73) 68·0% only vertebral IAD included SAH (25, 100%) 
Neurorad   Neurosurgery       0 IADs were bilateral   
2005               
Kurata43 24 Japan DSA in all 54 (35-71) 79·2% only vertebral IAD included SAH (24, 100%) 
AJNR    Neurosurgery           
2001               
Yamada44 24 Japan DSA in most 51 (35-71) 66·7% only vertebral IAD included SAH (24, 100%) 
J Neurosurg   Neurosurgery           
2004               
Zhao45 21 France DSA in all 43 (6-67) 52·4% only vertebrobasilar IAD included SAH (21, 100%) 
Acta Neurochir   Radiology       2 (9·5%) IADs were bilateral   
2007           VA (16), BA (5)   
Non-SAH vertebrobasilar IAD            
Arauz46 27 Mexico DSA (62%), CTA (22%),  40 66·7% only vertebrobasilar non-SAH IAD included ischaemic stroke (27, 100%) 
Eur J Neurol   Neurology MRA (16%)#         
2013               
Naito47 21 Japan DSA in all 50 (33-68) 61·9% only vertebral IAD non-SAH at first  cerebral ischaemia (11, 52·4%) 
Neurosurg   Neurosurgery       presentation included headache or neckpain (9, 42·9%) 







MRI /MRA and CTA in all,  
DSA in most 
51 (29-77) 84·8% only vertebrobasilar IAD included 
2 (6%)  bilateral IAD 
VA (25), BA (1), PICA (9) 
cerebral ischaemia (28, 84·9%) 
local symptoms (5, 15·2%) 
SAH posterior circulation non-vertebral artery  IAD          
Oran49 23 Turkey DSA in all, MRA (1) 52 (36-65) 30·4% only posterior circulation SAH included SAH (23, 100%) 
Diagn Interv    Radiology       BA (6), PCA (7), PICA (5), SCA (5)   
Radiol               
2009               
DSA=digital subtraction angiography. SAH=subarachnoid haemorrhage. ICA=internal carotid artery. MCA=middle cerebral artery. ACA=anterior cerebral artery. VA=vertebral artery.  
BA=basilar artery. PICA=posterior inferior cerebellar artery. PCoA=posterior communicating artery.  SCA=superior cerebellar artery. PCA= posterior cerebral artery. IAD=intracranial artery  
dissection. 
*, † these series partly overlap 
‡ series overlaps partly with Ahn, Radiology 2012; Kim, Stroke 2011; Kim, Neurology 2011 
§ numbers and percentages only reported for all patients with intra- and extracranial dissection (N=136), and not for subgroup of patients with IAD (N=22) 
| | one trauma patient excluded 
# percentages only reported for all patients with intra- and extracranial dissection (N=110), and not for subgroup of patients with IAD (N=27) 
  
Supplementary Table 2: Radiological criteria used for diagnosis of IAD in published series including more than 40 patients 
Paper Radiological criteria IAD 
Studies including more than 40 patients 
Yamaura1                              
Neuropathology 2000 
- tapered narrowing (string sign) or occlusion 
- aneurysmal outpouching (fusiform dilation) 
- intimal flap* 
- retention of contrast media into false lumen 
- combination of these findings like pearl and string sign 
Mizutani2                                            
J Neurosurg 2011 
- irregular stenosis 
- segmental stenosis and aneurysm formation (pearl and string) 
- irregular fusiform or aneurysmal dilation 
- double lumen* 
- occlusion 
- absence of markedly dilated lesions with significant elongation and tortuosity of the parent vessels 
- serial geometric change (on repeated angiographies) 
Ono3                         
Stroke 2013 
- typical pearl and string or double lumen sign at a non-branching site of the intracranial cerebral arteries on DSA 
- fusiform dilation with retention of contrast medium or angiographic steno-occlusive lesions accompanied by intramural haemorrhage detected on MRI at 
the same region on DSA* 
Kwak4 - double lumen* 
Neurointerv 2011 - luminal narrowing >30%  
  - gradual tapering ending in total occlusion 
  - aneurysmal pattern 
Metso5 - intramural haematoma* 
Stroke 2007 - intima flap or double lumen* 
  - long filiform stenosis 
  - occlusion that recanalisedsed into a long filiform stenosis (if in ICA, occlusion > 2 cm above carotid bifurcation) 
  - rat tail-shaped or flame-like occlusion 
  - fusiform aneurysm with arterial wall irregularity and no notable atherosclerosis, causing SAH 
Ahn 6                 
Radiology 2012 
- aneurysmal dilation of the intracranial vertebrobasilar arterial trunk 
- pearl-and-string sign (aneurysmal dilation alternating with stenosis) 
- tapered steno-occlusion 
- intramural haematoma* 
- intimal flap* 
- double lumen* 
Kim7 - aneurysmal dilation of the intracranial vertebrobasilar arterial trunk 
Stroke 2011 - pearl-and-string sign  
Matsukawa8 - intramural haematoma on fat suppression T1-weighted MRI or MRA* 
Cerebrovasc Dis 2012 - intimal flap* 
  - double lumen* 
  - string sign (smoothly tapered steno-occlusive lesion) 
  - pearl-and-string sign in the absence of atherosclerotic lesions 
  - aneurysmal dilation of the vertebral artery trunk not located at an arterial branching point and 
  associated with sudden headache or posterior ischaemic symptoms 
Kashiwasaki9 
Neuroradiology 2013 
- not specified 
Takemoto10 - pearl-and-string sign 
Acta Neurochir 2010 - string sign 
  - tapered occlusion 
  - intimal flap* 
  - intramural haematoma on T1 weighted image* 
Shin11 - on DSA: double lumen (false lumen or intimal flap)*, stenosis involving an irregular long or short segment 
Eur Neurol 2014  (pearl-and-string sign), occlusion of either the complete artery or a segment, or a  pseudoaneurysm associated with    
  a narrowed arterial lumen 
  - on CTA: a narrowed centric or eccentric lumen surrounded by crescent-shaped mural thickening (i.e. acute  
  thrombus sign in false lumen) and an associated increase in the external diameter*,  an abrupt or tapered 
   occlusive lumen with mural thickening and an associated increase in the external diameter, or an aneurysmally  
  dilated lumen or a dilated and narrowed lumen with or without crescent-shaped mural thickening or an intimal flap 
  - on MRA: long stenotic segments consistent with the ‘string sign’, tapered stenosis or occlusion, pseudoaneurysm,  intimal flap formation and luminal 
irregularity*, or the presence of a wall haematoma* 
Nakazawa12 - intimal flap or double lumen on angiogram* 
Neurorad J 2011 - intimal flap or double lumen on CTA* 
  - haematoma in the arterial wall on T1-weighted image of MRI* 
  - dilation and stenosis, retention of contrast media, string sign, pearl sign, tapered occlusion on angiogram 
  - dilation and stenosis on MRA or CTA 
  - intimal flap or double lumen on MRI, MRA; Enhanced volume T1WI* 
  - fusiform dilation of parent artery on angiogram, MRA, CTA 
  - chronological changes of the radiological findings and no cause except for dissection 
Jin13 - not specified 
AJNR 2009   
Zhao14 
Eur Radiol 2014 
- not specified 
Nakajima15                  
Acta Neurochir 2010 
- not specified 
Zhao16                           
Plos One 2013 
  
- fusiform dilation without stenosis in the affected vertebral trunk portion 
- irregular lateral dilation without stenosis in the affected vertebral trunk portion 
- fusiform or irregular dilation with stenosis ("pearl and string sign") 
Kim50                          
Neurology 2011 
- intramural haematoma on fat-suppression T1-weighted MR or MR angiogram source images* 
- intimal flap* 
- double lumen sign* 
- string sign (smoothly tapered steno-occlusive lesion) or pearl-and-string sign, without any atherosclerotic change of the involved artery 
- fusiform or irregular aneurysmal dilation of arterial trunk not located at arterial branching point, but associated with sudden onset of severe pulsatile 
headache or posterior ischaemic symptoms 
Kai17                     
Neurosurgery 2011 
- long stenotic segments exhibiting the ‘‘string sign’’  
- tapered stenosis or occlusion 
- pseudoaneurysm 
- intimal flap formation* 
- luminal irregularity 
- crescent-shaped high signal intensity within a vessel wall (mural haematoma or double lumen)* 
Matsukawa18 Major criteria 
JNNP 2014 - ‘Double lumen’ or ‘intimal flap’ demonstrated on either DSA, MRI, MRA, CTA or duplex ultrasonography* 
  -  ‘Pearl and string sign’ or ‘string sign’ demonstrated on DSA 
  -  Pathological confirmation on arterial dissection* 
  Minor criteria 
  - ‘Pearl sign’ or ‘tapered occlusion’ demonstrated on DSA 
  - ‘Pearl and string sign’, ‘string sign’ or ‘tapered occlusion’ demonstrated on MRA 
  -  ‘Hyperintense intramural signal’ (corresponding to intramural haematoma) demonstrated on T1-weighted MRI* 
  Additional criteria 
  - Change in arterial shape demonstrated on either DSA, MRI, MRA, CTA or duplex ultrasonography 
  -  No other causes of arterial abnormalities 
  Definite dissection 
    Presence of one or more major criteria, or presence of one or more minor criteria and both of two  additional 
   criteria 
  Probable dissection 
    Presence of one or more minor criteria 
DSA=digital subtraction angiography 




Supplementary Table 3: Treatment and outcome of IAD patients in published series including 20 to 40 patients 
	  
Paper N Treatment Follow-up Death Good functional 
outcome† 
Symptomatic recurrences or complications 
All types             
Lasjaunias19 33 SAH:  not specified 11·1% (2/18) not reported 16·7%  SAH 
Childs Nerv Syst   76·9% surgical or endovascular treatment     SAH: 22·2%     SAH: 23·1% rebleeding 
2005   15·4% no treatment    non-SAH: 0%     
    7·7% unknown         
    non-SAH         
    45·0% surgical or endovascular treatment          
    10·0% medical treatment with aspirin         
    15·0% no treatment         
    30·0% unknown         
Mohammadian20 30 SAH:  17 months 3·3% mRS≤3 0% SAH 
Neurol Res Int   100% endovascular treatment  (6-33 months) SAH: 4·0% 93·3% 20·0% cerebral ischaemia (peri-procedural) 
2013   non-SAH   non-SAH: 0%  SAH: 92%   
    100%  surgical or endovascular treatment       non-SAH: 100% 
Li21* 25 SAH:  90 days 12·0% mRS ≤3 0% SAH 
J Clin Neurosc   76·9% surgical or endovascular treatment    SAH: 7·7% 64·0% 0% cerebral ischaemia 
2011   23·1% unknown   non-SAH: 16·7% SAH: 46·2%   
    non-SAH     non-SAH: 83·3% 
    66·7% medical treatment with aspirin         
    16·7% anticoagulation treatment         
    16·7% surgical or endovascular treatment          
So22* 23 SAH:  16 months§ 17·4% mRS≤1 17·4% SAH 
Clin Neurol    100% endovascular treatment  (0-82 months)  SAH: 25·0% 65·2%  SAH: 25·0% rebleeding pre-treatment 
Neurosurg   non-SAH    non-SAH: 0%   13·0% cerebral ischaemia 
2014   100%  endovascular treatment         SAH: 12·5% cerebral ischaemia  (peri-procedural) 
             non-SAH: 14·3% cerebral ischaemia (peri-procedural) 
Pelkonen23 22 not reported not reported not reported not reported not reported 
Acta Radiol             
2004             
Wakhloo24 20 SAH:  20·6 months 0% not specified 5·0% SAH 
Stroke 
2008 
  100%  endovascular treatment  (3-156 months) SAH: 0% 65% 
asymptomatic 
 non-SAH: 5·9% SAH due to wire perforation 
   non-SAH   non-SAH: 0%   10·0% cerebral ischaemia 
    100%  endovascular treatment         non-SAH: 11·8% cerebral ischaemia 
SAH IAD             
Anxionnat25 27 63·0% endovascular treatment not defined 14·8% not defined 11·1% rebleeding (at 8·3 day [1-13]) 
Neurosurgery   37·0% treated "conservatively" (no details)     63·0% 7·4% ischaemic stroke (periprocedural) 
2003             
Wong26 23 100%  surgical or endovascular treatment  28 months 8·7% mRS≤2 8·7% rebleeding post-treatment 
Surg Neurol Int     (1-53 months)   60·9% 4·3%  ischaemic stroke (peri-procedural) 
2010           4·3% haemorrhagic stroke (peri-procedural) 
Vertebrobasilar IAD            
Rabinov27 34 SAH:  not reported 20·6% mRS≤1 13·3% SAH 
AJNR   79·3% surgical or endovascular treatment     SAH: 24·1% 53·3%  SAH: 6·9% rebleeding 
2003    21·7% no treatment    non-SAH: 0%  SAH: 48·0% 2·9% cerebral ischaemia due to extension of contralateral IAD 
    non-SAH:      non-SAH: 
80·0% 
 SAH: 3·4% cerebral ischaemia 
    100% surgical or endovascular treatment          
    100% endovascular treatment          
Hosoya28 31 80·6% antihypertensives and/or oral  not reported 0% "good recovery" not reported 
Stroke   anticoagulants     74·1%   
1999   9·7% endovascular treatment          
    9·7% surgical treatment          
Lee29 28 100% surgical or endovascular treatment  6 months 3·6% GOS 4-5 0 % SAH 
Yonsei Med J       SAH: 4·3% 98·3% 4·8% postoperative infection of cerebrospinal fluid 
2007       non-SAH: 0% SAH: 87·0% collection 
          non-SAH: 100% 
Park30†,‡ 27 100% endovascular treatment  28 months 3·7% mRS≤1 3·7% SAH 
AJNR     (7-50 months)  SAH: 9·1% 77·8%  SAH:9·1% rebleeding post-treatment 
2009        non-SAH: 0%  SAH: 63·6%   
           non-SAH: 87·5% 
Taha31 25 100% endovascular treatment  61·8 months 12·0% GOS 4-5 4·0% SAH 
Turk Neurosurg     (13- 120 
months) 
 SAH: 23·5% 84·0% 
 SAH: 5·9% rebleeding post-treatment 
2010        non-SAH: 0%  SAH: 23·5% 17·6% cerebral infarction 
           non-SAH: 100%    5·9% asymptomatic cerebral infarction 
Albuquerque32 23 100% endovascular treatment  14·6 months 8·7% "good recovery" 4·3% asymptomatic recurrence  (no details on type, retreated) 
Neurosurg Focus     (1-49 months) SAH: 11·8% 90·9% 4·3% headache due to recurrence (no details on type, treated) 
2003       non-SAH: 0%     
Lv33 22 100% endovascular treatment  37 months 0% GOS 5 0% SAH 
AJNR     (6-84 months)   100% 0% cerebral infarction 
2010             
Yoon34 22 100% endovascular treatment  16 months 0% mRS≤1 0% SAH  
Acta Neurochir     (1-60 months)   95·5% 9·1% proximal artery dissection during procedure 
2010          SAH: 83·3%   
           non-SAH: 100%   
Kim35† 21 SAH:  21·5 months 14·3% mRS≤2 19·0%  SAH 
AJNR   30·0% antihypertensives and/or anticoagulants (5-50 months)  SAH: 30·0% 71·4%  SAH:40·0% rebleeding 
2008   70·0% endovascular treatment     non-SAH: 0% SAH: 60·0% 4·8% brain stem compression (after 3 years, treated) 
    non-SAH:     non-SAH: 45·5% 
    63·6% antihypertensives and/or anticoagulants         




26 100% endovascular treatment 32·6 months 
(0-82 months) 
11·5% 
SAH : 21·4% 




non-SAH : 100%  
0% SAH 
SAH vertebrobasilar IAD          
Endo37 38 SAH only 6 months 15·8% mRS≤2 SAH only 
J Neurosurg   100%  surgical or endovascular treatment      60·5% 39·5% rebleeding pre-treatment (9 not confirmed on  
2013           imaging) 
 
          2·6% ischaemic stroke post-treatment 
Ramgren38 29 SAH only 6 months 27·6% GOS 5 SAH only 
Neurorad   51·7% endovascular treatment      55·2% 31·0% rebleeding (pre-treatment, within 12 days) 
2005   48·3% treated "conservatively"       6·9% cerebral ischaemia (TIA, periprocedural) 
            6·9% asymptomatic rupture IAD peri-procedural 
Yuki39 29 SAH only 23 months| | 17·2% mRS≤2 SAH only 
J Neurosurg   100% endovascular treatment  (1-132 months)   65·5% 6·9% rebleeding (1 before and 1 after treatment) 
2005           3·4% abcess at surgical site 
Shibukawa40 26 SAH only not reported 19·2% GOS 5 SAH only 
Hiroshima J Med Sci 100% endovascular treatment      46·2% 0% rebleeding after endovascular treatment 
2009             
Lee41 25 SAH only 44·7 months 24·0% GOS 4-5 SAH only 
Acta Neurochir   100% endovascular treatment  (3-93 months)   68·0% 48·0% rebleeding 
2010            44·0% rebleeding pre-treatment (mean 20·7  
            hours, (1-74)) 
             4·0% rebleeding post-treatment (day 20) 
            4·0% asymptomatic ischaemia 
Sugiu42 25 SAH only not reported 16·0% GOS 5 SAH only 
Neurorad   100% surgical or endovascular treatment      68·0% 48·0% rebleeding (12 pre-treatment, 1 during  
2005           treatment) 
             44·0%  within 24 hours 
            0% cerebral ischaemia 
Kurata43 24 SAH only 9 months 33·3% GOS 5 SAH only 
AJNR    87·5% endovascular treatment  (1 week- 39   54·2% 58·3% rebleeding pre-treatment (92·9% within first 24 hours) 
2001   8·3%  treated "conservatively" (no details)  months)     8·3% ischaemic stroke 
    16·7% no treatment         
Yamada44 24 SAH only 8·3 years 66·7% GOS 5 SAH only 
J Neurosurg    100% treated "conservatively" (no details), because of     33·3% 45·8% rebleeding 
2004   delayed diagnosis, bilateral VA lesion, spontaneous occlusion        4·2% symptomatic vasospasm 
    of VA at aneurysm, or poor clinical condition         
Zhao45 21 SAH only 13·8 months 23·8% "good recovery" SAH only 
Acta Neurochir   66·7% surgical or endovascular treatment      57·1% 14·3% rebleeding  
2007   33·3% treated "conservatively" (no details)       4·8% recurrent dissection (16 months) 
            14·3% cerebral ischaemia  
Non-SAH vertebrobasilar IAD          
Arauz46 27 non-SAH only 46·4 months# non-SAH only mRS≤2 non-SAH only 
Eur J Neurol   59·3% with anticoagulants   not reported non-SAH only no SAH 
2013   40·7% with antiplatelet agents     70·4% no recurrence in this group 
Naito47 21 non-SAH only 14 months non-SAH only "good recovery" non-SAH only 
Neurosurgery   42·9% endovascular treatment due to enlargement of   (4 days- 88  0% 85·7% 14·3% SAH (mean 17 months, (1 day- 51 months)) 
2002   aneurysm (2), large aneurysm (2), progression of dissection months)     0% cerebral ischaemia 
    (1), persistent double lumen (1)          




33 Non-SAH only 
93·9% medical treatment 
6·0% coil embolisation 
3 months non-SAH only 
not reported 
not reported not reported 
SAH posterior circulation non-vertebral artery  IAD          
Oran49 23 SAH only 25·5 months SAH only GOS 5 SAH only 
Diagn Interv    100% endovascular treatment  (20 days- 84  4·3% 47·8% 4·3% rebleeding post-treatment 
Radiol    91·3% endovascular treatment in acute phase months)     21·7% cerebral ischaemia 
2009             8·7%  TIA 
SAH=subarachnoid haemorrhage. mRS=modified Rankin scale score. IAD=intracranial artery dissection. GOS= Glasgow Outcome Scale.  TIA=transient ischaemic attack. 
*, † these series partly overlap 
‡ series overlaps partly with Ahn, Radiology 2012; Kim, Stroke 2011; Kim, Neurology 2011 
§ mean follow-up only reported for 19 survivors 
| | mean follow-up only reported for 18 survivors who were not lost to follow-up 
# mean follow-up only reported for all patients with intra- and extracranial dissection  (N=110), and not for subgroup of patients with IAD (N=27)
